Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends

This publication has 83 references indexed in Scilit:

• Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing
  Journal of Clinical Oncology, 2009
• Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
  Cancer Chemotherapy and Pharmacology, 2008
• Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy
  Annals of Oncology, 2008
• Cancer Statistics, 2008
  CA: A Cancer Journal for Clinicians, 2008
• Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
  New England Journal of Medicine, 2007
• Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy
  Journal of Clinical Oncology, 2007
• Molecular mechanisms of drug resistance
  The Journal of Pathology, 2005
• Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer
  Supportive Care in Cancer, 2003
• Breast Cancer Management
  PharmacoEconomics, 2003
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000